about
P112
P169
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines.Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis.Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune SystemThe Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ TransplantationType of RNA Packed in VLPs Impacts IgG Class Switching-Implications for an Influenza Vaccine Design
P50
Q33855899-60987DD3-E95E-4362-816C-307B312645CBQ37681112-ED2AB8C2-FE7E-494D-BDA7-4EEE42E9BE0FQ40087267-A4F03820-BC78-41C6-BC45-AD34E5108904Q47160110-48B2CA54-60E1-4517-A25C-541449DE1916Q50949437-3155287D-6E3A-4D5D-A1A9-007D66CDBA5AQ59357016-23E18057-0EDB-4440-AC20-57F55FA7E6D9Q91994540-536A1BEF-0160-494B-82EE-791613BB7A04Q92544100-D1D1E40D-7379-43E5-89EE-2992E7637D2A
P50
description
Scientific researcher and co-founder of baseimmune
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ariane C Gomes
@ast
Ariane C Gomes
@en
Ariane C Gomes
@es
Ariane C Gomes
@nl
Ariane C Gomes
@sl
type
label
Ariane C Gomes
@ast
Ariane C Gomes
@en
Ariane C Gomes
@es
Ariane C Gomes
@nl
Ariane C Gomes
@sl
altLabel
Ariane Gomes
@en
prefLabel
Ariane C Gomes
@ast
Ariane C Gomes
@en
Ariane C Gomes
@es
Ariane C Gomes
@nl
Ariane C Gomes
@sl
P106
P31
P496
0000-0002-3974-4088